𝔖 Bobbio Scriptorium

✦ LIBER ✦

Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients

✍ Scribed by Di Minno, Matteo Nicola Dario; Russolillo, Anna; Di Minno, Alessandro; Camera, Marina; Parolari, Alessandro; Tremoli, Elena

Book ID: 119977003
Publisher: Informa plc
Year: 2013
Tongue: English
Weight: 318 KB
Volume: 18
Category: Article
ISSN: 1472-8214
DOI: 10.1517/14728214.2013.777427

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

ATRIAL FIBRILLATION TREATMENT PARADOX: C

ATRIAL FIBRILLATION TREATMENT PARADOX: CHARACTERISTICS OF AND FIRST-YEAR EVENTS IN PATIENTS NOT TREATED WITH VITAMIN-K ANTAGONISTS COMPARED TO TREATED PATIENTS. THE GARFIELD REGISTRY

✍ Bassand, Jean-Pierre L.; Rushton-Smith, Sophie; Camm, A John; Goldhaber, Samuel 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 149 KB

Oral direct thrombin inhibitor AZD0837 f

Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: A Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy

✍ Gregory Y.H. Lip; Lars H. Rasmussen; S. Bertil Olsson; Sofia Zetterstrand; Chris 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 659 KB

Letter by Apostolakis et al Regarding Ar

Letter by Apostolakis et al Regarding Article, “Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R 2 CHADS 2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts”

✍ Apostolakis, Stavros ;Lane, Deirdre A. ;Banerjee, Amitava 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 419 KB